Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD).
Schneider RB, Omberg L, Macklin EA, Daeschler M, Bataille L, Anthwal S, Myers TL, Baloga E, Duquette S, Snyder P, Amodeo K, Tarolli CG, Adams JL, Callahan KF, Gottesman J, Kopil CM, Lungu C, Ascherio A, Beck JC, Biglan K, Espay AJ, Tanner C, Oakes D, Shoulson I, Novak D, Kayson E, Ray Dorsey E, Mangravite L, Schwarzschild MA, Simuni T; Parkinson Study Group AT-HOME PD Investigators. Schneider RB, et al. Among authors: gottesman j. Ann Clin Transl Neurol. 2021 Feb;8(2):308-320. doi: 10.1002/acn3.51236. Epub 2020 Dec 22. Ann Clin Transl Neurol. 2021. PMID: 33350601 Free PMC article.
American Football Play and Parkinson Disease Among Men.
Bruce HJ, Tripodis Y, McClean M, Korell M, Tanner CM, Contreras B, Gottesman J, Kirsch L, Karim Y, Martin B, Palmisano J, Abdolmohammadi B, Shih LC, Stein TD, Stern RA, Adler CH, Mez J, Nowinski C, McKee AC, Alosco ML. Bruce HJ, et al. Among authors: gottesman j. JAMA Netw Open. 2023 Aug 1;6(8):e2328644. doi: 10.1001/jamanetworkopen.2023.28644. JAMA Netw Open. 2023. PMID: 37566412 Free PMC article.
Characterization of treatment resistance and viral kinetics in the setting of single- versus dual-active monoclonal antibodies against SARS-CoV-2.
Choudhary MC, Deo R, Evering TH, Chew KW, Giganti MJ, Moser C, Ritz J, Regan J, Flynn JP, Crain CR, Wohl DA, Currier JS, Eron JJ, Margolis D, Zhu Q, Zhon L, Ya L, Greninger AL, Hughes MD, Smith D, Daar ES, Li JZ; ACTIV-2/A5401 Study Team. Choudhary MC, et al. J Infect Dis. 2024 May 8:jiae192. doi: 10.1093/infdis/jiae192. Online ahead of print. J Infect Dis. 2024. PMID: 38716969
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
Jagannathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Main MJ, Monk PD, Javan AC, Li JZ, Fletcher CV, McCarthy C, Wohl DA, Daar ES, Eron JJ, Currier JS, Singh U, Smith DM, Fischer W; ACTIV-2/A5401 Study Team. Jagannathan P, et al. EClinicalMedicine. 2023 Oct 6;65:102250. doi: 10.1016/j.eclinm.2023.102250. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37855026 Free PMC article.
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
Jilg N, Chew KW, Giganti MJ, Daar ES, Wohl DA, Javan AC, Kantor A, Moser C, Coombs RW, Neytman G, Hoover K, Jana A, Hart PA, Greninger AL, Szurgot B, Eron JJ, Currier JS, Hughes MD, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. Jilg N, et al. Clin Infect Dis. 2023 Oct 5;77(7):941-949. doi: 10.1093/cid/ciad342. Clin Infect Dis. 2023. PMID: 37279602 Clinical Trial.
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
Bender Ignacio RA, Chew KW, Moser C, Currier JS, Eron JJ, Javan AC, Giganti MJ, Aga E, Gibbs M, Tchouakam Kouekam H, Johnsson E, Esser MT, Hoover K, Neytman G, Newell M, Daar ES, Fischer W, Fletcher CV, Li JZ, Greninger AL, Coombs RW, Hughes MD, Smith D, Wohl DA; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)–2/A5401 Study Team. Bender Ignacio RA, et al. JAMA Netw Open. 2023 Apr 3;6(4):e2310039. doi: 10.1001/jamanetworkopen.2023.10039. JAMA Netw Open. 2023. PMID: 37099295 Free PMC article. Clinical Trial.
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Evering TH, Chew KW, Giganti MJ, Moser C, Pinilla M, Wohl DA, Currier JS, Eron JJ, Javan AC, Bender Ignacio R, Margolis D, Zhu Q, Ma J, Zhong L, Yan L, D'Andrea Nores U, Hoover K, Mocherla B, Choudhary MC, Deo R, Ritz J, Fischer WA, Fletcher CV, Li JZ, Hughes MD, Smith D, Daar ES; ACTIV-2/A5401 Study Team. Evering TH, et al. Ann Intern Med. 2023 May;176(5):658-666. doi: 10.7326/M22-3428. Epub 2023 Apr 18. Ann Intern Med. 2023. PMID: 37068272 Free PMC article. Clinical Trial.
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
Deo R, Choudhary MC, Moser C, Ritz J, Daar ES, Wohl DA, Greninger AL, Eron JJ, Currier JS, Hughes MD, Smith DM, Chew KW, Li JZ; ACTIV-2/A5401 Study Team. Deo R, et al. Ann Intern Med. 2023 Mar;176(3):348-354. doi: 10.7326/M22-2381. Epub 2023 Feb 21. Ann Intern Med. 2023. PMID: 36802755 Free PMC article. Clinical Trial.
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, Moser C, Hughes MD, Ritz J, Ribeiro RM, Ke R, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Fletcher CV, Daar ES, Wohl DA, Eron JJ, Currier JS, Parikh UM, Sieg SF, Perelson AS, Coombs RW, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. Choudhary MC, et al. Nat Microbiol. 2022 Nov;7(11):1906-1917. doi: 10.1038/s41564-022-01254-1. Epub 2022 Oct 26. Nat Microbiol. 2022. PMID: 36289399 Free PMC article. Clinical Trial.
89 results